Multi-omics characterization of CAF-related transcriptional programs reveals a smoking-context-informed 11-gene prognostic signature in HNSCC

BMC Cancer · Published 2026-08-04 · DOI 10.1186/s12885-026-16603-0

Free full text

Authors (4)

Tao Shi, Yuqing Wang, Lisheng Yu, Yixin Zhao

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Shi, T., Wang, Y., Yu, L., et al. (2026). Multi-omics characterization of CAF-related transcriptional programs reveals a smoking-context-informed 11-gene prognostic signature in HNSCC. BMC Cancer. https://doi.org/10.1186/s12885-026-16603-0

Related articles

• Tumor budding and tumor-associated lymphocytic response as histopathological indicators of high-risk disease in head and neck cutaneous squamous cell carcinoma · BMC Cancer · 2026 · Same journal
• Integrative transcriptomic and experimental analyses identifies SDF4 as an astrocyte-expressed regulator of glioma progression through PI3K-AKT signaling · BMC Cancer · 2026 · Same journal
• Investigation of the significance and role of androgen receptor expression in basal/squamous type urothelial carcinoma cell line J82 cells · BMC Cancer · 2026 · Same journal
• Precision oncology meets Generative AI: assessing large language models in multidisciplinary GIST tumor boards · BMC Cancer · 2026 · Same journal
• Senescence-related immunosuppressive gene MFAP2 orchestrates stromal-immune crosstalk and immunotherapy resistance in gastric cancer · BMC Cancer · 2026 · Same journal
• The impact of STAS on recurrence-free and overall survival in T1-2N0 adenocarcinomas: a single-center retrospective study · BMC Cancer · 2026 · Same journal
• Despite improved overall stratification, the 9th edition stage IIIA category remains prognostically heterogeneous: insights from a T3N2a subgroup analysis · BMC Cancer · 2026 · Same journal
• Characterisation of a novel p53 mutation (p53N263Tfs*7) associated with li-fraumeni syndrome · BMC Cancer · 2026 · Same journal
• Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models · BMC Cancer · 2026 · Same journal
• Trends in treatment and survival of stage IV non-squamous NSCLC from 2010 to 2022 · BMC Cancer · 2026 · Same journal